Main navigation
What We Do
What We Do
Investment Banking
Public Finance
Research
Fixed Income
Alternative Asset Management
Equities
Sectors
Sectors
Chemicals
Consumer
Education
Energy, Power & Infrastructure
Financial Services
Financial Sponsors
Government
Healthcare
Real Estate
Services & Industrials
Technology
About
About
Who We Are
Our Commitments
Our People
News & Insights
Conferences & Events
Careers
Investor Relations
Transactions
Transactions
Investment Banking
Public Finance
Contact
Search
Invalid search inquiry
Log In
Log In
Client Account Access
Fixed Income Client Portal
Merchant Banking Investor Access
Research Access
Read more
about Amgen-2022-08-30
$3.0 Billion
Image
Amgen Inc.
Senior Notes
Co-Manager
Read more
about ScholarRock-2023-10-13
Image
Scholar Rock Holding Corporation
Confidentially Marketed Follow-On Offering
Active Bookrunner
Read more
about Nuvalent-2023-10-17
$300.0 Million
Image
Nuvalent, Inc.
Follow-On Offering
Active Bookrunner
Read more
about MadrigalPharmaceuticals-2023-09-28
$499.9 Million
Image
Madrigal Pharmaceuticals, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
Read more
about Immunovant-2023-09-27
$322.0 Million
Image
Immunovant, Inc.
Follow-On Offering
PIPE
Active Bookrunner
Read more
about CymaBay-2023-09-13
$258.7 Million
Image
CymaBay Therapeutics, Inc.
Follow-On Offering
Active Bookrunner
Read more
about Crinetics-2023-09-12
$350.0 Million
Image
Crinetics Pharmaceuticals, Inc.
Follow-On Offering
Active Bookrunner
Read more
about Biohaven Ltd.-2023-10-02
$258.7 Million
Image
Biohaven Ltd.
Confidentially Marketed Follow-On Offering
Active Bookrunner
Read more
about ALX Oncology-2023-10-04
$63.2 Million
Image
ALX Oncology
Confidentially Marketed Follow-On Offering
Active Bookrunner
Read more
about TCR2-2023-03-06
TCR2 Therapeutics
TCR2 Therapeutics Inc. has combined with Adaptimmune Therapeutics
Financial Advisor
Pagination
Previous page
‹‹
Page 10
Next page
››
Subscribe to Biopharma
